Hormone Levels In Patients Research Articles

Effect of chronic neurogenic pain on blood levels of hormones in patients with melanoma depending on their gender.

e22097 Background: Chronic neurogenic pain (CNP) as a comorbid disease is quite frequent, but its effect on malignant diseases is poorly studied. The risk of cutaneous melanoma in women is higher, but the disease course in men is more severe. The purpose of the study was to reveal the effect of CNP on the levels of sex hormones in the blood of patients with melanoma depending on their gender. Methods: Blood levels of estradiol (E2), estrone (E1), progesterone (P4), testosterone (T) and prolactin (PRL) were measured by ELISA in patients with Т3-4NxM0 melanoma (M): 21 women with CNP (pelvic pain - 7, osteochondrosis – 14), mean age 67.2±2.7 years; 17 men with CNP (osteochondrosis), mean age 65.6±3.1 years. The control group included patients with melanoma similar in age, gender and disease stages without CNP. Results: In women with M+CNP, E2 and P4 were decreased by 1.8 times, while E1 was 1.4 times, T – 2 times, PRL – 1.5 times higher, compared to controls. In men with M+CNP, blood levels of estrogens were unchanged, PRL was 2.5 times lower and P4 and T – 1.3 times higher, compared to the corresponding control levels. Conclusions: CNP upregulated blood levels of androgens in both male and female melanoma patients, and caused the inversion of estrogens only in women with the prevalence of E1 over E2. Gender differences in the CNP influence included the elevation of progesterone and a decrease of prolactin in the blood of men, and P4 deficiency with increased prolactin in women with M+CNP. The specific effect of CNP on the hormonal profile in patients with cutaneous melanoma should be considered in choosing antitumor treatment.

T141. EFFECTS OF MENSTRUAL CYCLE ON RESTING STATE FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA: A FUNCTIONAL MRI STUDY

BackgroundThe menstrual cycle is a favorable model for examining the influence of ovarian hormones on cognition, emotion and brain functions. Ovarian hormones have substantial effects on task-related brain activity, but their impacts on functional connectivity at rest have been investigated by a few studies conducted with healthy individuals and these pre-existing findings are inconsistent. As for schizophrenia, different influences of ovarian hormones were reported. For instance, the estrogen hypothesis of schizophrenia has suggested that estrogen plays a neuroprotective role in the pathophysiology of this disorder. The present study investigates resting state functional connectivity (RS-FC) alterations related to menstrual cycle phase and/or hormone levels in patients with schizophrenia and healthy controls and aims to contribute to the understanding of the effects of ovarian hormones on the pathogenesis of schizophrenia and brain functions.MethodsThe study was conducted with 13 women with schizophrenia (the mean of age: 32 ± 7.67) and 13 healthy women (the mean of age: 30.08 ± 7.27). Resting state functional Magnetic Resonance Imaging (fMRI) scanning, as well as hormonal and clinical assessments, were applied to each participant twice, during two menstrual cycle phases: early follicular (Days 2–6; low estrogen/progesterone) and mid-luteal (Days 20–22; high estrogen/progesterone). The serum hormone levels of estradiol, progesterone, prolactin (only in the patients), follicle-stimulating and luteinizing were assessed. The clinical assessment interviews included the Brief Psychiatric Rating Scales, the Clinical Global Impression (only for the patients), the Global Assessment of Functioning and the Calgary Depression Rating Scale for Schizophrenia (for both groups).ResultsOur findings revealed that no cycle phase-related alterations existed in RS-FC in both groups. However, specific correlations between each hormone and RS-FC were found in both cycle phases for two groups. In the patients, estrogen was positively correlated with the auditory network (AN) connectivity in the left amygdala at the early follicular phase. In the controls, the positive correlations to progesterone were found in the precuneus for the connectivity of the posterior default mode network (DMN) and the left-frontoparietal network (FPN) during the early follicular phase. Also, progesterone was negatively correlated with the executive control network (ECN) connectivity in the right superior frontal gyrus at the mid-luteal phase in the controls. Furthermore, the patients had lower progesterone levels during the mid-luteal phase compared to the controls (p<0.05). The severity of the psychotic symptoms of the patients didn’t change between the cycle phases.DiscussionTo our knowledge, this is the first study to examine the influence of the menstrual cycle on the brain’s RS-FC in schizophrenia. Our results indicated that the effects of the menstrual cycle on RS-FC were more prominent in the controls rather than the patients with schizophrenia; and that the findings for the patient group may be associated with the additional mechanisms responsible from schizophrenia. This might imply that differentiating the menstrual cycle effects is difficult in a complex disorder such as schizophrenia. The results obtained from the controls are consistent with the previous findings indicating that the menstrual cycle effects might be associated with the connectivity of the DMN and cognition-related networks. Moreover, our results suggested that estrogen might have a modulating effect on the intrinsic functional connectivity changes in the patients, while progesterone, might mediate to that in the controls.

OR11-05 Clinical Characteristics and Reproductive Hormone Levels in 201 Men With Congenital and 479 Men With Acquired Hypogonadotropic Hypogonadism: A Single-Center Comparative Study

Context. Hypogonadotropic hypogonadism (HH) is a clinical condition defined by subnormal serum testosterone levels with low serum gonadotropins, which leads to infertility and reduced testicular function in men. HH may be prenatal or congenital (CHH) or acquired (AHH), the latter most commonly related to injury at the hypothalamic/pituitary level. Since diverse medical specialists usually deal with these two disorders, a direct comparison of clinical characteristics and reproductive hormone levels in patients with CHH and AHH has never been performed in a large series. Patients and methods. 201 men with CHH (Kallmann syndrome 52%; normosmic CHH 48%) and 479 men with AHH were included. Causes for AHH included pituitary tumors (74.6%), other intracranial tumors (12.7%; craniopharyngioma 9.1%), infiltrative diseases (3.5%), and other causes (9.2%). We excluded patients with idiopathic late-onset or metabolically-related AHH from this analysis. Testicular volume (TV), serum gonadotropins, total and bioavailable testosterone (TT and BT), estradiol (E2) and testicular peptides inhibin B (IB), AMH and INSL3 were measured at a single center in the absence of any hormone replacement. Results. TV was greater in patients with AHH (16.2±6.3 mL) than in those with CHH (3.4±2.7 mL; p<0.0001). Testicular hypotrophy (mean TV<12 mL) was found in 30% of patients with AHH and in 97% of those with CHH (p<0.0001). When adjusted for age and BMI, men with AHH still had a larger mean TV than those with CHH (p<0.0001). Cryptorchidism was more frequent in patients with CHH than in those with AHH (20.4 vs 0.2%, p<0.0001). Micropenis was found exclusively in patients with CHH. TT levels were higher in patients with AHH (1.4±0.9 ng/mL) than in those with CHH (0.4±0.3 mL, p<0.0001). LH, FSH, BT and E2 were higher in patients with AHH than in those with CHH (p<0.0001 for all parameters), as were IB and INSL3 levels (126±87 vs 59±55 pg/mL, and 566±372 vs 60±40 pg/mL, respectively, p<0.001). In contrast, serum AMH and SHBG levels were lower in patients with AHH than in those with CHH (246±234 vs 46±38 pmol/L, and 35±22 vs 26±21 nmol/L, respectively, p<0.0001). Comparing hormone characteristics across different AHH subgroups, patients with craniopharyngioma (n=44) had lower TV (7.7±5.3 mL) and lower TT, BT, E2, IB and INSL3 levels than those with AHH caused by any other etiology (p<0.05 for all parameters). Conclusions. Our data demonstrate distinct profiles of clinical presentation and reproductive hormones between CHH and AHH. Clinical and hormonal impairment is more severe in patients with CHH than in those with AHH. Preservation of the gonadotrope/testicular axis activity during the fetal, neonatal and pubertal periods in patients with AHH likely accounts for these differences. Among AHH etiologies, patients with craniopharyngioma have the most severe impairment, likely as a result of the intrinsic severity of these tumors, the age at onset, and/or the aggressiveness of the available therapeutic procedures.

Detection of CYP21A2 gene mutations and the differences in the levels of hormones in patients with 21-hydroxylase deficiency

Objective: To analyze the detection of CYP21A2 gene mutations in 21-hydroxylase deficiency (21-OHD) patients, so as to determine the accuracy of clinical diagnosis. Methods: Totally, 514 patients with 21-OHD who visited Peking Union Medical College Hospital from January 2015 to January 2018 were enrolled and their clinical and biochemical data were collected. DNAs were extracted from peripheral blood leukocytes and CYP21A2 mutations were detected by Sanger sequencing and multiple ligation probe amplification (MLPA) technique. We divided 514 patients into three groups: two mutations of CYP21A2 alleles (group A), one mutation of CYP21A2 (group B), and no mutation of CYP21A2 (group C). Results: Mutation was detected in each allele of CYP21A2 gene in 401 (78.0%) patients, ninety (17.5%) had only one mutant allele and 23 (4.5%) had no mutation. There was no significant difference between the patients with different clinical phenotypes and the number of CYP21A2 gene mutations detected. In male, the cortisol of the patients with simple virilizing 21-OHD in group A [0.04 (0.02, 0.20) nmol/L] was lower than that of group B [0.24 (0.17, 0.28) nmol/L] and the difference was statistically significant (P=0.014). In female, 17-hydroxyprogesterone (17-OHP) of patients with salt wasting 21-OHD in group A [153.7 (90.1, 204.5) nmol/L] was higher than that of group B [38.2 (31.0, 183.3) nmol/L] and C [42.6 (27.8, 48.1) nmol/L] and the differences were statistically significant (both P<0.05). The progesterone of patients with simple virilizing 21-OHD in group C [23.0 (8.6, 33.2) nmol/L] was lower than that of gourp A [57.8 (34.4, 110.2) nmol/L] and B [63.6 (31.4, 110.8) nmol/L] and the difference were statistically significant (both P<0.05). The 17-OHP of patients with non-classical 21-OHD in group C [24.5 (20.4, 54.2) nmol/L] was lower than that of group A [158.7 (59.1, 187.6) nmol/L] and B [147.8 (131.9, 179.3) nmol/L]. The difference were statistically significant (both P<0.05). Conclusions: Mutations of two alleles have not been found in all patients with clinically diagnosed 21-OHD. Other congenital adrenal hyperplasia (CAH) types which can cause similar changes in 17-OHP and other hormones may be misdiagnosed as 21-OHD. Therefore, 21-OHD cannot be diagnosed with help of 17-OHP level only, and gene detection plays a vital role in the differential diagnosis of different CAH types.

Determinants of High Parathyroid Hormone Levels in Patients With Severe Obesity and Their Relationship With the Cardiometabolic Risk Factors, Before and After a Laparoscopic Sleeve Gastrectomy Intervention.

Obesity is a risk factor for vitamin D deficiency and hyperparathyroidism. Hyperparathyroidism could exert a negative effect on glucose metabolism and vascular function. The aim of this study was to identify the determinants of hyperparathyroidism beyond vitamin D deficiency, whether hyperparathyroidism could have a negative impact on individual health and whether laparoscopic sleeve gastrectomy (LSG) negatively affects the levels of intact parathyroid hormone (iPTH) and 25(OH) vitamin D (25(OH)D). We evaluated the levels of iPTH, 25(OH)D, and leptin, together with markers of insulin sensitivity and early cardiovascular disease, in a cohort of 160 patients with severe obesity before and after an LSG intervention. Ninety-seven percent of subjects had vitamin D deficiency, and 72% of them had hyperparathyroidism. After correcting for possible confounders, we found a correlation between iPTH levels and carotid intima-media thickness, as well as with the HOMA index. After the LSG, 25(OH)D levels were significantly increased, while iPTH levels were significantly reduced. The reduction of iPTH was significantly correlated with the reduction of BMI, diastolic blood pressure, and leptin, which was the independent predictor of iPTH reduction. Our results suggest that vitamin D deficiency is not the sole determinant of hyperparathyroidism in severe obesity because visceral fat deposition and leptin could both play a role. Obesity-related hyperparathyroidism is associated with insulin resistance and atherosclerosis, although the results from previous studies were conflicting. Finally, LSG intervention does not negatively affect vitamin D status and improves hyperparathyroidism.

Clinical observation and analysis of thyroid hormone levels in patients with idiopathic membranous nephropathy

We sought to investigate the effect of total triiodothyronine (TT3) reduction in the follow-up of patients with idiopathic membranous nephropathy (IMN). A total of 121 patients were enrolled and classified into a low TT3 group or a normal group. Clinical indicators were compared between the groups, and changes in estimated glomerular filtration rate (eGFR), albumin (ALB), thyroid-stimulating hormone, serum creatinine, total protein, total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) during follow-up were analysed. In the analysis by TT3 level, ALB was significantly lower in the low TT3 group (P < .05), while TC, TG, LDL-C, fibrinogen, and renal pathological staging were significantly higher in the low TT3 group (P < .05). Analysis of variance for repeated measurement during follow-up showed that there were no significant differences in eGFR and ALB between the groups. TC, TG, and LDL-C levels were significantly higher in the low TT3 group (P < .05). Approximately 37% of patients with IMN showed a decrease in TT3, which was accompanied by significantly decreased ALB level, higher pathological stage, and increased serum lipid level compared with patients having a normal TT3 level. The management of TT3, and appropriate intervention, may therefore help to prevent the kidney damage progress in patients with IMN.

Outcome of laparoscopic uterine artery occlusion for uterine fibroids on ovarian function and complications in patients with uterine fibroid

Objective: The aim of this study is to investigate the outcome of laparoscopic uterine artery occlusion (LUAO) on ovarian function in the treatment of uterine fibroid and its influence on complications.Materials and Methods: A total of 61 patients with uterine fibroid accept LUAO from January 2013 to December 2015 were selected as the research objects. The changes of ovarian hormone secretion volume, internal blood supply of uterine fibroid, uterine volume, fibroid volume, and the occurrence of complications were observed before and 3, 6, 12, and 24 months after surgery. These results were compared with the outcomes of 63 patients with uterine fibroid accept myomectomy.Results: Compared with myomectomy treatment, the length of intraoperative blood loss, operation time, and hospitalization time of patients in the LUAO group were shorter (P < 0.05). Menstruation characteristics, uterine volume, and uterine fibroid volume postoperation were better than the prior ones in the LUAO group (P < 0.05). The ovarian secretion of luteinizing hormone, estradiol, and follicle-stimulating hormone levels in patients in the following 24 months after surgery were not statistically different in two groups (P > 0.05), and the pelvic floor function had similar results.Conclusion: Uterine fibroid treated by LUAO is effective, it can decrease the internal blood supply of uterine fibroid, narrow the volume of uterine fibroid, and little impaction on ovarian function. Hence, this kind of treatment is worthy of promotion.

Association between serum 25-hydroxyvitamin d and early recurrent ischemic stroke

Aim: Vitamin D deficiency has been reported as a new risk factor for ischemic stroke in recent years. However, the pathophysiological mechanisms between recurrent ischemic stroke and decreased 25-hydroxyvitamin D [25(OH) D] are not clear. The aim of this study is to examine the relationship between initial vitamin D levels and early recurrent stroke in patients presenting with acute ischemic stroke (AIS).Material and Methods: Four hundreds and ten consecutive patients who were followed-up with AIS diagnosis were included in the study. Risk factors for ischemic stroke were questioned and biochemical and cardiac examinations of the patients were performed. Simultaneously, the National Institutes of Health Stroke Scale (NIHSS) was calculated. Patients who had recurrent ischemic stroke obtained retrospectively were from the hospital registry system in last three month. The patients were divided into two groups as those who had recurrent stroke and who did not.Results: A total of 410 patients, 187 of which were female (45.6%) and 223 of which were male (54.4%) with a mean age of 68.12 ± 12.63 (29-99) were included in the study. Early recurrent ischemic stroke was detected in 48 (11.7%) patients in the follow-up. The systolic blood pressure and diastolic blood pressures at the time of first consultation were higher in the recurrent ischemic stroke group compared to the non-recurrent ischemic stroke group (p0.001). Serum total vitamin D and serum parathyroid hormone levels in patients without recurrent stroke were higher as compared with those in patients with recurrent stroke (p0.001). 25(OH) D were significantly associated with stroke recurrence (OR:1.277;Cl 95%, 1.166-1.398; p0.001).Conclusion: Our study showed that decreased serum 25 (OH)D in patients presenting with acute ischemic stroke is associated with recurrent ischemic stroke in the early stage.

Correlation of Cutaneous Manifestations with Body Mass Index, Blood Glucose, and Hormonal Levels in Patients with Polycystic Ovarian Disease.

Background:Polycystic ovarian disease (PCOD) is characterized by oligo/anovulation, ultrasonographic evidence of polycystic ovaries and cutaneous features such as hirsutism, acne, acanthosis nigricans, androgentic alopecia, and signs of virilization.Aim:Correlation of dermatological manifestations with body mass index (BMI), blood glucose, and levels of free testosterone, dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), and luteinizing hormone (LH) in patients of PCOD hailing from Pimpri, Pune.Subjects and Methods:This observational study was carried out from November 2015–April 2017 on 102 patients (aged 12–45 years, non-pregnant) of PCOD, attending dermatology/gynecology outpatient departments. After recording socio-demographic/menstrual and medical history, BMI was calculated and examination of cutaneous manifestations were done. Participants were then subjected to pelvic ultrasonography and blood sugar/hormonal estimation.Statistical Analysis:By using statistical package for the Social Sciences 17.0 software, Chi-square test, and Fisher's exact test.Results:Age: 59.80% belonged to the third decade (range,12–40; mean, 26.27 ± 5.05 years); ultrasonography revealed polycystic ovaries in 79.41%. Cutaneous manifestations recorded were – acne (74.50%); acanthosis nigricans (50%); striae (49.02%); hirsutism (40.19%); acrochordons (36.27%); seborrheic dermatitis (32.35%), and androgenetic alopecia (30.39%). Free testosterone (35;34.31%), DHEAS (9;8.82%), LH and FSH (2;1.96% each), and LH: FSH ratio (51;50%) were raised. Statistical association of acanthosis nigricans emerged with free testosterone (P = 0.034), DHEAS (P = 0.016), fasting blood sugar (P = 0.01), and raised BMI (P = 0.002) and of hirsutism with raised DHEAS (P = 0.016), free testosterone (P = 0.012), and BMI (P = 0.022).Conclusion:Significant correlations demonstrated were acanthosis nigricans with free testosterone, DHEAS, FBS, and BMI and hirsutism with DHEAS, free testosterone, and BMI.

The impact of body mass index on reproductive hormones, testosterone/estradiol ratio and semen parameters.

IntroductionThe aim of this study was to evaluate the relationship between body mass index (BMI) and sperm parameters and reproductive hormone levels in patients with no known risk factors for infertility.Material and methodsFour hundred patients who met the study’s inclusion criteria were divided into three groups according to their BMI values as normal weight (BMI: 18.5–24.9 kg/m2), overweight (BMI 25–29.9 kg/m2), and obese (BMI ≥30 kg/m2). Semen parameters, reproductive hormone levels and testosterone/estradiol ratio were compared retrospectively between the groups.ResultsThere was no significant difference between the groups in terms of age and infertility period. The mean BMI of all the patients was 26.6 ±4.08, and the BMI in the normal, overweight and obese groups were 22.6 ±1.7, 27.4 ±1.3, and 33.4 ±2.9, respectively (p <0.001). There was no significant difference between the groups in terms of serum follicle stimulating hormone, luteinizing hormone, estradiol, prolactin, semen volume, sperm concentration, total sperm count, and progressive and total motility. Serum testosterone (T) level and testosterone/estradiol (T/E2) ratio were significantly higher in the normal BMI group (p <0.001).ConclusionsAdipose tissue increase was not significantly correlated with change in the semen parameters and it was negatively correlated with T levels and T/E2 ratio.

Analysis of thyroid hormone levels in patients with hearing disorders in the Republic of Buryatia: search for Pendred syndrome phenotypes

Analysis of thyroid hormone levels in patients with hearing disorders in the Republic of Buryatia: search for Pendred syndrome phenotypes

Effect of ovarian granulosa cell androgen receptor splice variant on endocrine hormone levels in patients with polycystic ovary syndrome

Effect of ovarian granulosa cell androgen receptor splice variant on endocrine hormone levels in patients with polycystic ovary syndrome

Serum parathyroid hormone levels in patients with chronic right heart failure.

Parathyroid hormone (PTH) is a novel cardiovascular biomarker which is particularly useful for detection and assessment of heart failure (HF). However, previous studies examining PTH in heart failure have primarily focused on left HF; thus, the relationship between PTH and right HF remains unclear. The aim of the present study was to evaluate the serum PTH levels in patients with chronic right HF. A total of 154 patients with chronic right HF were enrolled in the present study. A binary logistic regression analysis model was used to assess the independent predictive value of PTH levels in chronic right HF. Partial correlative analysis was used to demonstrate the relevance of PTH levels on the parameters of assessment of right heart function. A multiple linear regression analysis model was used to evaluate the independent factors of PTH levels in patients with right HF. The results showed that the serum PTH levels in the right HF group were significantly higher compared with the control group. After adjusting for predictors of right HF, serum PTH levels were associated with right HF with an odds ratio of 1.066 (95% confidence interval: 1.030-1.102, P<0.001. Serum PTH levels were independently correlated with plasma N-terminal pro-B-type natriuretic peptide levels, right ventricular end-diastolic diameter and severity of lower extremity edema (all P<0.05). Therefore, based on the results of the present study, PTH may be a useful biomarker for detection and assessment of right HF.

Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis.

To perform a structured systematic review and meta-analysis to evaluate changes in ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and gastric inhibitory peptide (GIP) gut hormone levels in patients after sleeve gastrectomy. Despite sleeve gastrectomy becoming the most common surgical weight loss procedure, weight loss mechanisms remain less clear. Searches of PubMed, EMBASE, Web of Science, and Cochrane Library databases were performed through April 1, 2019, in accordance with PRISMA and MOOSE guidelines. Randomized controlled trials and prospective observational studies evaluating pre and post-procedure hormones fasting ghrelin, postprandial GLP-1, postprandial PYY, and fasting GIP levels were included. Hedge g with random-effects models were used to determine pooled effect size and corresponding 95% confidence intervals (CIs). A total of 28 studies (n = 653; 29.56% male) were included. Mean age was 42.00 ± 5.48 years, with average follow-up of 11.70 ± 11.38 months. Pre-procedure body mass index (BMI) was 46.01 ± 4.07 kg/m with a postsleeve gastrectomy BMI of 34.07 ± 3.73 kg/m, representing total body weight loss of 25.13 ± 4.44% and excess weight loss of 57.48 ± 9.64% (P < 0.001). Ghrelin decreased (Hedge g -1.486, 95% CI -1.884 to -1.089, I = 91.95%), whereas GLP-1 and PYY increased post-procedure (Hedge g 1.095, 95% CI 0.509 to 1.642, I = 84.38%; and Hedge g 1.396, 95% CI 0.781 to 2.011, I = 84.02%, respectively). GIP did not significantly change (Hedge g -0.213, 95% CI -1.019 to 0.592, I = 79.65%). Fasting ghrelin levels decreased, whereas postprandial GLP-1 and PYY increased after sleeve gastrectomy. Fasting GIP levels remained unchanged. Future studies are needed to assess the role of these gut hormones and relationship to weight loss and metabolic outcomes.

1128 Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-Analysis

INTRODUCTION: Despite sleeve gastrectomy becoming the most common surgical weight loss procedure, weight loss mechanisms remain less clear. The primary aim of this study was to perform a structured systematic review and meta-analysis of all eligible studies to evaluate changes in various gut hormone levels in patients following sleeve gastrectomy. METHODS: Searches of PubMed, EMBASE, Web of Science, and the Cochrane Library databases were performed through April 1, 2019 in accordance with PRISMA and MOOSE guidelines. Measured outcomes included pre- and post-operative hormones: fasting ghrelin, post-prandial glucagon-like peptide-1 (GLP-1), post-prandial peptide YY (PYY), and fasting gastric inhibitory peptide (GIP) levels. Hedge’s g was used to determine pooled effect size and corresponding 95% confidence intervals (CIs). Heterogeneity was assessed with Cochran Q test and I 2 statistics. Study quality was evaluated with the Newcastle-Ottawa Quality Assessment Scale (NOS) score for observational studies and JADAD score for randomized controlled trials. Publication bias was evaluated by funnel plot using Egger and Begg tests. RESULTS: A total of 28 studies (n = 653; 29.56% male) were included. Mean age was 42.00 ± 5.48 years with average follow-up of 11.70 ± 11.38 months. Pre-procedure BMI was 46.01 ± 4.07 kg/m2 with a post-sleeve gastrectomy BMI of 34.07 ± 3.73 kg/m2 (%EWL 57.48 ± 9.64). Ghrelin decreased [Hedge’s g of -1.486 (95% CI, -1.884 to -1.089); I 2 = 91.95%; Q-value of 310.57] while GLP-1 and PYY increased post-procedure [Hedge’s g of 1.095 (95% CI, 0.509 to 1.642); I 2 = 84.38%; Q-value of 70.43) and Hedge’s g of 1.396 (95% CI, 0.781 to 2.011); I 2 = 84.02%; Q-value of 62.59), respectively]. GIP did not significantly change [Hedge’s g of -0.213 (95% CI, -1.019 to 0.592; I 2 = 79.65%; Q-value of 4.92]. Baseline characteristics as stratified by individual gut hormone are shown in Table 1. Quality assessment revealed all studies to be of high quality (i.e., NOS score ≥4 or JADAD score of ≥3). Classic fail-safe determined it would take 2044, 244, and 248 non-significant studies to nullify the difference in gut hormone levels for ghrelin, GLP-1, and PYY, respectively. CONCLUSION: Ghrelin levels decrease while post-prandial GLP-1 and PYY increase after sleeve gastrectomy. GIP levels remain unchanged. Future studies are needed to assess the role of these gut hormones and relationship to weight loss and metabolic outcomes. These results may have the potential to optimize patient selection in an era personalized medicine.

Adjuvant therapy of acupoint catgut embedding for threatened abortion after in vitro fertilization-embryo transfer: a randomized controlled trial

To observe the effects of acupoint catgut embedding on miscarriage prevention and pregnancy outcome in patients with threatened abortion after in vitro fertilization-embryo transfer (IVF-ET). Sixty cases of patients with threatened abortion after IVF-ET were randomly divided into an observation group and a control group, 30 cases in each group. The patients in the control group were treated with intramuscular injection of progesterone (40 mg) once every day, while the patients in the observation group, on the basis of the treatment of control group, were treated with catgut embedding at Geshu (BL 17), Ganshu (BL 18), Shenshu (BL 23), Pishu (BL 20), Weishu (BL 21), Xuehai (SP 10), Diji (SP 8) and Fuliu (KI 7), once every two weeks, six times as a course of treatment. The treatment was given until 12 weeks into pregnancy. The level of serum human chorionic gonadotropin (HCG), estradiol (E2) and progesterone (P) before and after treatment was recorded; the TCM syndrome score before and after treatment was compared; the successful pregnancy rate and spontaneous abortion rate after treatment were observed in the two groups. Compared before treatment, the scores of TCM syndrome in both groups were reduced after treatment (both P<0.01), and score in the observation group was superior to that in the control group (P<0.05). After treatment, the clinical efficacy in the observation group was superior to that in the control group (P<0.05). After treatment, the hormone levels (β-HCG, E2, P) in both groups were increased steadily; the hormone levels in 6-week pregnancy, 8-week pregnancy and 10-week pregnancy were significantly higher than those in 4-week pregnancy (all P<0.05); except the levels of P and β-HCG in 10-week pregnancy, the hormone levels in the observation group were superior to those in the control group (all P<0.05). After treatment, the early abortion rate was 16.7% (5/30) in the observation group, which was lower than 33.3% (10/30) in the control group (P<0.01); the pregnancy rate was 96.0% (24/25) in the observation group, which was higher than 80.0% (16/20) in the control group (P<0.01). Acupoint catgut embedding is effective for preventing threatened abortion, which could significantly reduce the spontaneous abortion rate, improve the pregnancy success rate, regulate hormone levels in patients after IVF-ET.

The Effect of Ramadan fasting on thyroid hormone levels in patients on levothyroxine treatment

The Effect of Ramadan fasting on thyroid hormone levels in patients on levothyroxine treatment

Serum Antimullerian Hormone Levels in Patients Who Underwent Uterine Artery Ligation

Serum Antimullerian Hormone Levels in Patients Who Underwent Uterine Artery Ligation

CHOROIDAL THICKENING AND PACHYCHOROID IN CUSHING SYNDROME

To investigate subfoveal choroidal thickness and pachychoroid and their correlation with hormone level in patients with endogenous Cushing syndrome (CS). We enrolled a consecutive series of patients with CS and healthy controls. All participants had swept-source optical coherence tomography. All patients with CS had hormone test including morning plasma-free cortisol, 24-hour urine-free cortisol (24UFC), and plasma adrenocorticotropic hormone. We compared subfoveal choroidal thickness and pachychoroid changes between two groups. We performed univariate and multivariate analysis to study correlation between hormone level and choroid thickness as well as pachychoroid in patients with CS. Compared with control group, Cushing group had significantly greater subfoveal choroidal thickness (371.6 ± 114.9 and 320.0 ± 74.0, P = 0.002) and higher proportion of eyes with pachychoroid (53.1 and 14.3%, P < 0.001). Subfoveal choroidal thickness was significantly correlated with 24UFC (P = 0.007) but not with plasma-free cortisol (P = 0.48) or adrenocorticotropic hormone (P = 0.56). Pachychoroid was significantly correlated with 24UFC (P = 0.03) but not with plasma-free cortisol (P = 0.24) or adrenocorticotropic hormone (P = 0.32). There was a positive correlation between elevated 24UFC and choroid thickening as well as pachychoroid, indicating the importance of normal endogenous cortisol level in maintaining the human choroid vasculature.

Effect of X-ray on serum thyroxin hormone level in patients undergoing brain computed tomography in Port Harcourt

Effect of X-ray on serum thyroxin hormone level in patients undergoing brain computed tomography in Port Harcourt